[go: up one dir, main page]

MX2019014365A - Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos. - Google Patents

Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos.

Info

Publication number
MX2019014365A
MX2019014365A MX2019014365A MX2019014365A MX2019014365A MX 2019014365 A MX2019014365 A MX 2019014365A MX 2019014365 A MX2019014365 A MX 2019014365A MX 2019014365 A MX2019014365 A MX 2019014365A MX 2019014365 A MX2019014365 A MX 2019014365A
Authority
MX
Mexico
Prior art keywords
inflammatory bowel
topical treatment
antibodies
fragments
bowel disease
Prior art date
Application number
MX2019014365A
Other languages
English (en)
Inventor
Abdul Waseh Basit
Vipul Yadav
Varum Felipe José Oliveira
Gonzalez Roberto Carlos Bravo
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MX2019014365A publication Critical patent/MX2019014365A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere al uso terapéutico de composiciones que contienen moléculas de anticuerpo y fragmentos funcionales de las mismas, por ejemplo, moléculas de anticuerpo y fragmentos funcionales capaces de unirse al factor alfa de necrosis del tumor (TNFa), en el tratamiento tópico de enfermedades intestinales inflamatorias, que incluyen enfermedad de Crohn y colitis ulcerativa.
MX2019014365A 2017-05-31 2018-04-26 Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos. MX2019014365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17173847.9A EP3409688A1 (en) 2017-05-31 2017-05-31 Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
PCT/EP2018/060690 WO2018219559A1 (en) 2017-05-31 2018-04-26 Topical treatment of inflammatory bowel disease using antibodies and fragments thereof

Publications (1)

Publication Number Publication Date
MX2019014365A true MX2019014365A (es) 2020-09-10

Family

ID=59021292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014365A MX2019014365A (es) 2017-05-31 2018-04-26 Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos.

Country Status (10)

Country Link
US (2) US11717484B2 (es)
EP (3) EP3409688A1 (es)
JP (2) JP7288863B2 (es)
KR (1) KR102699072B1 (es)
AR (1) AR111901A1 (es)
CA (1) CA3060598A1 (es)
ES (1) ES2981901T3 (es)
MX (1) MX2019014365A (es)
TW (1) TW201902511A (es)
WO (1) WO2018219559A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409688A1 (en) * 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
WO2020114616A1 (en) * 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
BR112022010035A2 (pt) * 2019-11-27 2022-08-16 Dsm Ip Assets Bv Comprimido de mups compreendendo riboflavina
AR122407A1 (es) 2020-03-31 2022-09-07 Chemocentryx Inc Composiciones y métodos para tratar la inflamación intestinal usando un inhibidor de ccr9 y anticuerpos de bloqueo anti-il-23
CN113577299B (zh) * 2021-05-27 2023-09-05 浙江大学医学院附属第一医院 一种ros响应性的单抗类药物口服纳米粒及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
FI20000780A7 (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
EP1891110A2 (en) 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2008127105A1 (en) * 2007-04-16 2008-10-23 Friesland Brands B.V. Milk derived antigen specific antibodies, methods of preparation and uses thereof
US8647626B2 (en) 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
ES2861592T3 (es) 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
DK2307458T3 (en) 2008-06-25 2018-07-16 Esbatech Alcon Biomed Res Unit Humanization of rabbit antibodies using a universal antibody framework
CA2730178A1 (en) 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
PT2488202E (pt) 2009-10-15 2015-10-19 Avaxia Biologics Inc Agentes terapêuticos à base de anticorpos de atividade local no tracto digestivo
EP3409688A1 (en) * 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof

Also Published As

Publication number Publication date
CA3060598A1 (en) 2018-12-06
EP4371610A3 (en) 2024-08-14
JP2023071894A (ja) 2023-05-23
AR111901A1 (es) 2019-08-28
US20200170956A1 (en) 2020-06-04
TW201902511A (zh) 2019-01-16
EP4371610A2 (en) 2024-05-22
KR102699072B1 (ko) 2024-08-26
JP7288863B2 (ja) 2023-06-08
US11717484B2 (en) 2023-08-08
KR20200019905A (ko) 2020-02-25
EP3630823A1 (en) 2020-04-08
WO2018219559A1 (en) 2018-12-06
JP2020523298A (ja) 2020-08-06
EP3409688A1 (en) 2018-12-05
ES2981901T3 (es) 2024-10-14
US20240000714A1 (en) 2024-01-04
EP3630823B1 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2025009223A (es) Agentes de union a clec9a y su uso
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12018502429A1 (en) Antibody molecules for cancer treatment
NZ754051A (en) Novel antibodies and uses thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
EP4276114A3 (en) Cd20 binding single domain antibodies
MX2025008493A (es) Agentes de union a fibroblastos y uso de estos
MX2019014365A (es) Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos.
WO2016187220A3 (en) Anti-ror1 antibodies
MX2018006477A (es) Anticuerpos y metodos de uso de estos.
PH12017501583A1 (en) Novel proteins specific for cd137
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
SA523440622B1 (ar) أجسام مضادة
PL423259A1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12021551419A1 (en) New conjugated nucleic acid molecules and their uses
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases